Luo et al.23, in their study investigating the efficacy of LG in a non-alcoholic fatty liver disease (NAFLD) model in diabetic mice, reported that the levels of TNF-α, IL-1β, and IL-6 were high in the NAFLD group and that the levels of inflammatory cytokines decreased, and hepatic steatosis regressed with LG. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.